Celecoxib inhibits the lytic activation of Kaposi’s sarcoma-associated herpesvirus through down-regulation of RTA expression by inhibiting the activation of p38 MAPK

Viruses

Volumn 7, Issue 5, 2015, Pages 2268-2287

  Chen, Jungang ^a,b   Jiang, Liangyu ^a,b   Lan, Ke ^c   Chen, Xulin ^a,b  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c INSTITUTE PASTEUR OF SHANGHAI   (China)

Author keywords

Celecoxib; Kaposi s sarcoma associated herpesvirus; P38 MAPK; RTA

Indexed keywords

CELECOXIB; ESTERASE; GENOMIC DNA; MITOGEN ACTIVATED PROTEIN KINASE P38; REPLICATION AND TRANSCRIPTION ACTIVATOR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; IMMEDIATE EARLY PROTEIN; RTA PROTEIN, HUMAN HERPESVIRUS 8; TRANSACTIVATOR PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; ENZYME INACTIVATION; FLUORESCENCE ANALYSIS; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; KAPOSI SARCOMA; LUCIFERASE ASSAY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INFECTIVITY; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN HERPESVIRUS 8; PHYSIOLOGY; VIRUS ACTIVATION;

HERPESVIRIDAE; HUMAN HERPESVIRUS 8;

ANTIVIRAL AGENTS; CELECOXIB; DOWN-REGULATION; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 8, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; TRANS-ACTIVATORS; VIRUS ACTIVATION;

EID: 84929303298     PISSN: 19994915     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7052268     Document Type: Article

References (60)

1. Chang, Y.; Cesarman, E.; Pessin, M.S.; Lee, F.; Culpepper, J.; Knowles, D.M.; Moore, P.S. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994, 266, 1865–1869.
2. Vazquez, E.D.; Kaye, K.M. Rapid and quantitative assessment of KSHV LANA-mediated DNA replication. Arch. Virol. 2011, 156, 1323–1333.
3. Antman, K.; Chang, Y. Kaposi’s Sarcoma. N. Engl. J. Med. 2000, 342, 1027–1038.
4. Dittmer, D.P.; Krown, S.E. Targeted therapy for Kaposi’s sarcoma and Kaposi’s sarcoma-associated herpesvirus. Curr. Opin. Oncol. 2007, 19, 452–457.
5. Miller, G.; Heston, L.; Grogan, E.; Gradoville, L.; Rigsby, M.; Sun, R.; Shedd, D.; Kushnaryov, V.M.; Grossberg, S.; Chang, Y. Selective switch between latency and lytic replication of Kaposi’s sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J. Virol. 1997, 71, 314–324.
6. Renne, R.; Zhong, W.; Herndier, B.; McGrath, M.; Abbey, N.; Kedes, D.; Ganem, D. Lytic growth of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat. Med. 1996, 2, 342–346.
7. Staskus, K.A.; Zhong, W.; Gebhard, K.; Herndier, B.; Wang, H.; Renne, R.; Beneke, J.; Pudney, J.; Anderson, D.J.; Ganem, D. et al. Kaposi’s sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J. Virol. 1997, 71, 715–719.
8. Parravicini, C.; Chandran, B.; Corbellino, M.; Berti, E.; Paulli, M.; Moore, P.S.; Chang, Y. Differential viral protein expression in Kaposi’s sarcoma-associated herpesvirus-infected diseases-Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. Am. J. Pathol. 2000, 156, 743–749.
9. Su, L.; Liao, Q.; Wu, Y.; Chen, X. Kaposi’s Sarcoma-Associated Herpesvirus-Encoded LANA Down-Regulates IL-22R1 Expression through a cis-Acting Element within the Promoter Region. PLOS ONE 2011, 6, e19106.
10. Ballestas, M.E.; Chatis, P.A.; Kaye, K.M. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 1999, 284, 641–644.
11. Corte-Real, S.; Collins, C.; Aires da Silva, F.; Simas, J.P.; Barbas, C.F., 3rd; Chang, Y.; Moore, P.; Goncalves, J. Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells. Blood 2005, 106, 3797–3802.
12. Gradoville, L.; Gerlach, J.; Grogan, E.; Shedd, D.; Nikiforow, S.; Metroka, C.; Miller, G. Kaposi’s sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line. J. Virol. 2000, 74, 6207–6212.
13. Vieira, J.; Huang, M.L.; Koelle, D.M.; Corey, L. Transmissible Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with a history of Kaposi’s sarcoma. J. Virol. 1997, 71, 7083–7087.
14. Sun, R.; Lin, S.-F.; Gradoville, L.; Yuan, Y.; Zhu, F.; Miller, G. A viral gene that activates lytic cycle expression of Kaposi’s sarcoma-associated herpesvirus. Proc. Natl. Acad. Sci. 1998, 95, 10866–10871.
15. Ye, F.; Lei, X.; Gao, S.-J. Mechanisms of Kaposi’s Sarcoma-Associated Herpesvirus Latency and Reactivation. Adv. Virol. 2011, 2011, 1–19.
16. Deng, H.; Liang, Y.; Sun, R. Regulation of KSHV lytic gene expression. Curr. Top. Microbiol. Immunol. 2007, 312, 157–183.
17. An, J.; Sun, Y.; Sun, R.; Rettig, M.B. Kaposi’s sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: The role of the NF-[kappa]B and JNK//AP1 pathways. Oncogene 2003, 22, 3371–3385.
18. Deutsch, E.; Cohen, A.; Kazimirsky, G.; Dovrat, S.; Rubinfeld, H.; Brodie, C.; Sarid, R. Role of protein kinase C delta in reactivation of Kaposi’s sarcoma-associated herpesvirus. J. Virol. 2004, 78, 10187–10192.
19. Guasparri, I.; Keller, S.A.; Cesarman, E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J. Exp. Med. 2004, 199, 993–1003.
20. Pan, H.; Xie, J.; Ye, F.; Gao, S.-J. Modulation of Kaposi’s Sarcoma-Associated Herpesvirus Infection and Replication by MEK/ERK, JNK, and p38 Multiple Mitogen-Activated Protein Kinase Pathways during Primary Infection. J. Virol. 2006, 80, 5371–5382.
21. Xie, J.; Pan, H.; Yoo, S.; Gao, S.J. Kaposi’s sarcoma-associated herpesvirus induction of AP-1 and interleukin 6 during primary infection mediated by multiple mitogen-activated protein kinase pathways. J. Virol. 2005, 79, 15027–15037.
22. Xie, J.; Ajibade, A.O.; Ye, F.; Kuhne, K.; Gao, S.-J. Reactivation of Kaposi’s sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. Virology 2008, 371, 139–154.
23. Cohen, A.; Brodie, C.; Sarid, R. An essential role of ERK signalling in TPA-induced reactivation of Kaposi’s sarcoma-associated herpesvirus. J. Gen. Virol. 2006, 87, 795–802.
24. Ford, P.W.; Bryan, B.A.; Dyson, O.F.; Weidner, D.A.; Chintalgattu, V.; Akula, S.M. Raf/MEK/ERK signalling triggers reactivation of Kaposi’s sarcoma-associated herpesvirus latency. J. Gen. Virol. 2006, 87, 1139–1144.
25. Gantt, S.; Casper, C. Human herpesvirus 8-associated neoplasms: The roles of viral replication and antiviral treatment. Curr. Opin. Infect. Dis. 2011, 24, 295–301.
26. Myoung, J.; Ganem, D. Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: Maintenance of tight latency with efficient reactivation upon induction. J. Virol. Methods 2011, 174, 12–21.
27. Vieira, J.; O’Hearn, P.M. Use of the red fluorescent protein as a marker of Kaposi’s sarcoma-associated herpesvirus lytic gene expression. Virology 2004, 325, 225–240
28. Yoo, S.M.; Ahn, A.K.; Seo, T.; Hong, H.B.; Chung, M.A.; Jung, S.D.; Cho, H.; Lee, M.S. Centrifugal enhancement of Kaposi’s sarcoma-associated virus infection of human endothelial cells in vitro. J. Virol. Methods 2008, 154, 160–166.
29. Lu, F.; Stedman, W.; Yousef, M.; Renne, R.; Lieberman, P.M. Epigenetic Regulation of Kaposi’s Sarcoma-Associated Herpesvirus Latency by Virus-Encoded MicroRNAs That Target Rta and the Cellular Rbl2-DNMT Pathway. J. Virol. 2010, 84, 2697–2706.
30. Lu, M.; Suen, J.; Frias, C.; Pfeiffer, R.; Tsai, M.H.; Chuang, E.; Zeichner, S.L. Dissection of the Kaposi’s sarcoma-associated herpesvirus gene expression program by using the viral DNA replication inhibitor cidofovir. J. Virol. 2004, 78, 13637–13652.
31. Marechal, V.; Lallemand, F.; Desire, N.; Rozenbaum, W.; Nicolas, J.C. Quantitative analysis of human herpesvirus 8 viral load using a real-time PCR assay. J. Clin. Microbiol. 2000, 38, 1404–1408.
32. Asahi-Ozaki, Y.; Sato, Y.; Kanno, T.; Sata, T.; Katano, H. Quantitative Analysis of Kaposi Sarcoma–Associated Herpesvirus (KSHV) in KSHV-Associated Diseases. J. Infect. Dis. 2006, 193, 773–782.
33. Yoo, S.M.; Zhou, F.-C.; Ye, F.-C.; Pan, H.-Y.; Gao, S.-J. Early and sustained expression of latent and host modulating genes in coordinated transcriptional program of KSHV productive primary infection of human primary endothelial cells. Virology 2005, 343, 47–64.
34. Xu, J.; Wang, J.; Deng, F.; Hu, Z.; Wang, H. Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitro. Antiviral. Res. 2008, 78, 242–249.
35. Lan, K.; Kuppers, D.A.; Verma, S.C.; Robertson, E.S. Kaposi’s Sarcoma-Associated Herpesvirus-Encoded Latency-Associated Nuclear Antigen Inhibits Lytic Replication by Targeting Rta: A Potential Mechanism for Virus-Mediated Control of Latency. J. Virol. 2004, 78, 6585–6594.
36. Pica, F.; Serafino, A.; Garaci, E.; Volpi, A. Cidofovir on HHV-8 in BCBL-1 cells. Antivir. Ther. 2004, 9, 823–825.
37. Friborg, J., Jr.; Kong, W.; Hottiger, M.O.; Nabel, G.J. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999, 402, 889–894.
38. Leung, H.J.; Duran, E.M.; Kurtoglu, M.; Andreansky, S.; Lampidis, T.J.; Mesri, E.A. Activation of the Unfolded Protein Response by 2-Deoxy-D-Glucose Inhibits Kaposi’s Sarcoma-Associated Herpesvirus Replication and Gene Expression. Antimicrob. Agents Chemother. 2012, 56, 5794–5803.
39. Guito, J.; Lukac, D.M. KSHV Rta Promoter Specification and Viral Reactivation. Front. Microbiol. 2012, 3, e30.
40. George Paul, A.; Sharma-Walia, N.; Chandran, B. Targeting KSHV/HHV-8 Latency with COX-2 Selective Inhibitor Nimesulide: A Potential Chemotherapeutic Modality for Primary Effusion Lymphoma. PLOS ONE 2011, 6, e24379.
41. Sharma-Walia, N.; Raghu, H.; Sadagopan, S.; Sivakumar, R.; Veettil, M.V.; Naranatt, P.P.; Smith, M.M.; Chandran, B. Cyclooxygenase 2 Induced by Kaposi’s Sarcoma-Associated Herpesvirus Early during In Vitro Infection of Target Cells Plays a Role in the Maintenance of Latent Viral Gene Expression. J. Virol. 2006, 80, 6534–6552.
42. Chun, K.S.; Kim, S.H.; Song, Y.S.; Surh, Y.J. Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin. Carcinogenesis 2004, 25, 713–722.
43. Bromberg, J.; Darnell, J.E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19, 2468–2473.
44. Aoki, Y.; Feldman, G.M.; Tosato, G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003, 101, 1535–1542.
45. Grösch, S.; Maier, T.J.; Schiffmann, S.; Geisslinger, G. Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors. J. Natl. Cancer Inst. 2006, 98, 736–747.
46. Niederberger, E.; Tegeder, I.; Vetter, G.; Schmidtko, A.; Schmidt, H.; Euchenhofer, C.; Bräutigam, L.; Grösch, S.; Geisslinger, G. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-?B. FASEB 2001, 15, 1622–1624.
47. Funakoshi-Tago, M.; Shimizu, T.; Tago, K.; Nakamura, M.; Itoh, H.; Sonoda, Y.; Kasahara, T. Celecoxib potently inhibits TNFa-induced nuclear translocation and activation of NF-?B. Biochem. Pharmacol. 2008, 76, 662–671.
48. Kim, S.-H.; Song, S.-H.; Kim, S.-G.; Chun, K.-S.; Lim, S.-Y.; Na, H.-K.; Kim, J.; Surh, Y.-J.; Bang, Y.-J.; Song, Y.-S. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-?B as a possible target. J. Cancer Res. Clin. Oncol. 2004, 130, 551–560.
49. Schonthal, A.H. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br. J. Cancer 2007, 97, 1465–1468.
50. Shelby, B.D.; Nelson, A.; Morris, C. Herpesvirus neoplasia: A growing role for COX-2. Microsc. Res. Tech. 2005, 68, 120–129.
51. Steer, S.A.; Corbett, J.A. The role and regulation of COX-2 during viral infection. Viral. Immunol. 2003, 16, 447–460.
52. Sharma-Walia, N.; Paul, A.G.; Bottero, V.; Sadagopan, S.; Veettil, M.V.; Kerur, N.; Chandran, B. Kaposi’s Sarcoma Associated Herpes Virus (KSHV) Induced COX-2: A Key Factor in Latency, Inflammation, Angiogenesis, Cell Survival and Invasion. PLOS Pathog. 2010, 6, e1000777.
53. Sharma-Walia, N.; Patel, K.; Chandran, K.; Marginean, A.; Bottero, V.; Kerur, N.; Paul, A.G. COX-2/PGE2: Molecular ambassadors of Kaposi’s sarcoma-associated herpes virus oncoprotein-v-FLIP. Oncogenesis 2012, 1, e5.
54. Paul, A.G.; Chandran, B.; Sharma-Walia, N. Concurrent targeting of EP1/EP4 receptors and COX-2 induces synergistic apoptosis in KSHV and EBV associated non-Hodgkin lymphoma cell lines. Trans. Res. 2013, 161, 447–468.
55. Lipsky, P.E.; Isakson, P.C. Outcome of specific COX-2 inhibition in rheumatoid arthritis. J. Rheumatol. Suppl. 1997, 49, 9–14.
56. Hubbard, R.C.; Koepp, R.J.; Yu, S.; Talwalker, S.; Geis, G.S.; Wiesenhutter, C.W.; Makarowski, W.S.; Paulus, H.A. SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study. Arthritis. Rheum. 1996, 39, 1188–1188.
57. Shi, S.J.; Klotz, U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur. J. Clin. Pharmacol. 2008, 64, 233–252.
58. Steinbach, G.; Lynch, P.M.; Phillips, R.K.S.; Wallace, M.H.; Hawk, E.; Gordon, G.B.; Wakabayashi, N.; Saunders, B.; Shen, Y.; Fujimura, T. et al. The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis. N. Engl. J. Med. 2000, 342, 1946–1952.
59. Rusnak, K.; Roloff, G.; Singh, S. Celecoxib and Cardiac Abnormalities: A Biostatistical Analysis of Adverse Side Effects. FASEB J. 2015, 29, 10.
60. Kim, B.J.; Kim, H.S.; Lee, J.Y.; Kim, H.O.; Park, Y.M.; La, H.O. Symmetrical drug-related intertriginous and flexural exanthema caused by celecoxib. Int. J. Dermatol. 2014, 53, e1–e3.